Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. (Q54478536)

30 May 2018

title

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer. (English)

1 reference

30 May 2018

single-nucleotide polymorphism

main subject

1 reference

1

1 reference

30 May 2018

Carlos Camps

2

1 reference

30 May 2018

author name string

M Cobo

3

1 reference

30 May 2018

R De las Peñas

4

1 reference

30 May 2018

B Massuti

5

1 reference

30 May 2018

R Blanco

6

1 reference

30 May 2018

V Alberola

7

1 reference

30 May 2018

U Jimenez

8

1 reference

30 May 2018

J R Delgado

9

1 reference

30 May 2018

F Cardenal

10

1 reference

30 May 2018

M Tarón

11

1 reference

30 May 2018

J L Ramírez

12

1 reference

30 May 2018

A Sanchez

13

1 reference

30 May 2018

R Rosell

14

1 reference

30 May 2018

publication date

29 September 2012

1 reference

30 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

30 May 2018

volume

70

1 reference

30 May 2018

page(s)

883-890

1 reference

30 May 2018

issue

6

1 reference

30 May 2018

https://scigraph.springernature.com/pub.10.1007/s00280-012-1985-9

exact match

0 references

cites work

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Multidrug resistance in cancer: role of ATP-dependent transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Aurora kinases as anticancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Cell cycle kinases as therapeutic targets for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Maximal chromosome compaction occurs by axial shortening in anaphase and depends on Aurora kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Overexpression of Aurora-A contributes to malignant development of human esophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1985-9

10.1007/S00280-012-1985-9

21 January 2018

Identifiers

DOI

1 reference

30 May 2018

PubMed ID

23053267

1 reference

30 May 2018